Halozyme Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence.
HALO Key Statistics
Stock Snapshot
As of today, Halozyme Therapeutics(HALO) shares are valued at $72.79. The company's market cap stands at 8.56B, with a P/E ratio of 15.79.
On 2026-01-08, Halozyme Therapeutics(HALO) stock traded between a low of $72.20 and a high of $75.51. Shares are currently priced at $72.79, which is +0.8% above the low and -3.6% below the high.
Halozyme Therapeutics(HALO) shares are trading with a volume of 2.05M, against a daily average of 1.67M.
During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $79.50 at its peak.
During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $79.50 at its peak.
HALO News
Leerink notes Halozyme (HALO) issued a press release announcing that it entered into an exclusive license agreement with Takeda (TAK) in December 2025 to develo...
(RTTNews) - Halozyme Therapeutics, Inc. (HALO), Thursday announced that the company has entered a global collaboration and exclusive license agreement with Take...
If you are asking whether Halozyme Therapeutics at around US$73.13 is still priced attractively, you are exactly who this breakdown is for. The stock has logge...
Analyst ratings
60%
of 10 ratingsMore HALO News
In Q3 CY2025, Halozyme Therapeutics reported results that exceeded market revenue expectations with 22.1% year-on-year growth and issued full-year guidance impl...
Halozyme Therapeutics (HALO) and Skye Bioscience (SKYE) announced the companies entered into a non-exclusive global collaboration and license agreement in Decem...